*

Hitt og þetta 24. apríl 2007

BioXell S.p.A. Shareholders unanimously approve all Board of Directors' proposals at A

Milan, Italy, April 24, 2007 - Shareholders of BioXell S.p.A. (SWX: BXLN) unanimously approved all items proposed by the Board of Directors at today's Annual General Meeting in Zurich. These included: * the approval of the 2006 statutory financial statements of BioXell S.p.A. * the appointment of Dr. Werner Lanthaler as member of the Board of Directors * the re-election of KPMG S.p.A. as External Auditors of the company * the increase of the authorized capital reserved to the beneficiaries of the company's stock option plan * the increase of the authorized capital reserved for strategic investments up to a maximum of 50% of the existing share capital, thus granting the company the flexibility to actively pursue strategic investments and in-licensing of complementary therapeutics within its areas of focus. The Annual General Meeting was attended by Shareholders who represented 54.87% of the total share capital of the Company. Dr. Thomas Szucs, Chairman of BioXell, commented, "It's an exciting time to be a Shareholder and participate in the BioXell story, as the Company enters a new phase in its maturation, with the goal of becoming a fully integrated biopharmaceutical company and a key player in the management of urological disorders. BioXell reached key milestones in 2006 in the development of Elocalcitol for two major urological disorders, Benign Prostatic Hyperplasia and Overactive Bladder, either of which represents a potential blockbuster market for the Company's lead compound. Furthermore, Elocalcitol will be entering clinical trials for a third indication, Male Infertility, later this year, while a new compound acquired from Roche will be advanced into Phase II trials for Post-Surgical Adhesions in 2008." About BioXell BioXell (SWX: BXLN) is a biopharmaceutical company focused on the discovery and development of drugs that exploit novel mechanisms of action to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company was founded in 2002 as a spin-out from Roche. BioXell's strategic goal is to become a fully integrated pharmaceutical company by maximizing the commercial potential of its product portfolio and leveraging existing platforms into profitable partnerships. BioXell's lead compound, Elocalcitol, derived from its proprietary VD3 (Vitamin D3) technology platform, is in Phase II clinical trials for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB), with a third Phase II trial for Male Infertility scheduled for 2007. In addition, the Company has several follow-on programs based on both VD3 and other technological platforms. BXL746 is to enter Phase II trials for Post-Surgical Adhesions in 2008. In 2006, BioXell in-licensed from Lay Line Genomics S.p.A. a novel anti-TrkA monoclonal antibody, MNAC13, which represents an innovative new approach to the treatment of pain. BioXell also has an exclusive partnership with Merck & Co., Inc. since 2005 for the development of its TREM platform, with TREM-1 in development for the treatment of septic shock. In June 2006, BioXell listed its shares on the main segment of the SWX Swiss Exchange. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: http://www.bioxell.com For further information, please contact: BioXell S.p.A. Rochat & Partners Alvise Sagramoso/Angela Evans Christophe Lamps/Jonathan Leighton Tel: +39 (0)2 210 49 51 Tel: +41 22 718 37 46 Fax: +39 (0)2 210 49 529 Fax: +41 22 786 54 58 alvise.sagramoso@bioxell.com clamps@rochat-pr.ch angela.evans@bioxell.com jleighton@rochat-pr.ch Disclaimer This press release does not constitute or form part, or all, of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of BioXell, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of BioXell, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. BioXell disclaims any obligation to update these forward-looking statements to reflect future events or developments. --- End of Message --- bioXell S.p.A via Olgettina 58 Milan Italy WKN: A0J3MW; ISIN: IT0004069933 ; Listed: Main Market in SWX Swiss Exchange;